Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion

Anti-VEGF antibody therapy with bevacizumab provides significant clinical benefit in patients with recurrent glioblastoma multiforme (GBM). Unfortunately, progression on bevacizumab therapy is often associated with a diffuse disease recurrence pattern, which limits subsequent therapeutic options. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huveldt, Deborah, Lewis-Tuffin, Laura J., Carlson, Brett L., Schroeder, Mark A., Rodriguez, Fausto, Giannini, Caterina, Galanis, Evanthia, Sarkaria, Jann N., Anastasiadis, Panos Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572988/
https://www.ncbi.nlm.nih.gov/pubmed/23457577
http://dx.doi.org/10.1371/journal.pone.0056505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572988/
https://www.ncbi.nlm.nih.gov/pubmed/23457577
http://dx.doi.org/10.1371/journal.pone.0056505

Ejemplares similares